Unicycive Therapeutics Stock (NASDAQ:UNCY)

Forecast Ownership Financials Chart

Previous Close

$0.65

52W Range

$0.20 - $1.21

50D Avg

$0.59

200D Avg

$0.53

Market Cap

$77.09M

Avg Vol (3M)

$938.03K

Beta

2.15

Div Yield

-

UNCY Company Profile

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

22

IPO Date

Jul 12, 2021

Website

UNCY Performance

UNCY Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	$675.00K	$951.00K
Operating Income	$-32.12M	$-20.77M	$-18.05M
Net Income	$-37.82M	$-30.54M	$-18.06M
EBITDA	$-32.12M	$-30.18M	$-18.05M
Basic EPS	$-0.06	$-1.28	$-1.20
Diluted EPS	$-0.06	$-1.28	$-1.20

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
RNAZ	TransCode Therapeutics, Inc.
CDIO	Cardio Diagnostics Holdings, Inc.